Meeting
2013 ASCO Annual Meeting
Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.
Authors
Luis Costa
Hospital de Santa Maria and Instituto de Medicina Molecular, Lisbon, Portugal
Luis Costa , Karim Fizazi , Fred Saad , Janet Elizabeth Brown , Roger Von Moos , Stephane Oudard , Cora N. Sternberg , Vinod Ganju , Kurt Miller , Huei Wang , Tapan Maniar , Ada Braun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00330759 and NCT00321620
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5079)
DOI
10.1200/jco.2013.31.15_suppl.5079
Abstract #
5079
Poster Bd #
40F
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE).
First Author: Arnoud J. Templeton
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2016 ASCO Annual Meeting
Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors.
First Author: Zefei Jiang
Poster
2014 Genitourinary Cancers Symposium
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.
First Author: Matthew R. Smith